Pharmacokinetics and Bioequivalence of Doxycycline (Providox® and Doxyvet
0-50 S®) Oral Powder Formulations in Chickens
Tariq M. Hantash,
Ehab A. Abu-Basha,
Dergham A. Roussan
Alaeldein M. Abudabos
A bioequivalence and pharmacokinetics profiles of two doxycycline powder formulations
(Providox® and Doxyvet 0-50 S®) were compared
in 24 healthy chickens following administration of a single oral dose (20 mg/kg
bw). Serial blood samples were drawn at 10 points after administration to determine
doxycycline concentrations in chicken plasma by HPLC/UV. the pharmacokinetics
parameters; area under plasma concentration-time curve (AUC0-24),
maximum plasma concentration (Cmax) were determined for both formulations.
The average means of AUC0-24 and Cmax for
Providox® and Doxyvet 0-50 S® were very close
(62.32 ± 3.34 and 57.55 ± 4.66 µg.h/ml and 5.36 ±
0.26 and 5.08 ± 0.25 µg/ml, respectively) with no significant differences
based on ANOVA. The 90% confidence intervals of the parameters AUC0-24 and Cmax between two formulations were within the range
80 to 125 % of bioequivalence according to US FDA regulation. The relative bioavailability
of Providox® compared to Doxyvet 0-50 S® was 108.24%.
Therefore, the Providox® and Doxyvet 0 - 50 S®
were considered to be bioequivalent.
Cited References Fulltext